Replication-enhanced oncolytic adenovirus
By inserting CMV and SV40 promoter/enhancer into the adenovirus genome and combining genome modification, the problem of low replication rate of existing oncolytic adenovirus vectors is solved, significantly improving viral replication and transgene expression in tumor cells, and improving the The efficiency of cancer treatment.
Patent Information
- Application Number
- CN202080077419.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-11-06
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2040-11-06
AI Technical Summary
The existing oncolytic adenovirus vectors have low replication rates in tumor cells, resulting in low therapeutic efficiency, and the presence of nonspecific infection and anti-adenovirus immunogenicity leads to vector clearance and neutralization, limiting their application in cancer treatment.
Viral replication and transgene expression in tumor cells are significantly enhanced by inserting CMV promoter/enhancer and SV40 early promoter/enhancer into the adenovirus genome, and combining modifications of E1A, E1B and E3 genomes, viral replication and transgene expression in tumor cells are formed. Recombinant oncolytic adenovirus.
It significantly improves the viral replication rate and tumor lysis ability in tumor cells, enhances the expression of therapeutic transgenes in tumor cells, and improves the effect of cancer treatment.
Smart Images

Figure HDA0003630030180000011 
Figure HDA0003630030180000021 
Figure HDA0003630030180000031
Abstract
Description
[0001] Joint Research Agreement
[0002] This invention is the result of activities performed within the scope of a joint research agreement in effect at the time the invention was made. The parties to the joint research agreement are Memgen, Inc. (formerly Memgen, LLC) and the H. Lee Moffitt Cancer Center and Research Institute, Inc. Background of the Invention
[0003] Field of the Invention
[0004] The present invention relates generally to the fields of oncolytic viruses and oncology. More specifically, the present invention relates to oncolytic virus compositions with enhanced viral replication in tumor cells for the treatment of cancer.
[0005] Description of the Prior Art
[0006] Oncolytic viruses are a class of cancer therapeutic agents with a dual mechanism of action: 1) killing tumor cells through selective viral replication in tumor cells, resulting in direct tumor lysis; 2) inducing systemic anti-tumor immunity by releasing antigens from destroyed tumor cells. Both native viruses and genetically modified viruses are under development. The first oncolytic virus, talimogene laherparepvec (IML 1), was approved by the U.S. FDA in 2015. Amgen Inc., Thousand Oaks, CA), a genetically modified herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) for topical treatment of melanoma, as described by Kohlhapp et al. in Clinical Cancer Research, 2016. However, herpes viruses are only one of many oncolytic viruses being investigated for their oncolytic properties.
[0007] Oncolytic adenoviral vectors are widely used in cancer gene therapy for several reasons, including broad tropism for infection of multiple tumor types, vector stability, ability to manufacture and purify virus at high titers, transgene carrying capacity, lack of integration into the host genome, and a favorable safety profile.
[0008] Despite these desirable properties of oncolytic adenoviral vectors, the use of these vectors in cancer therapy is limited for a variety of reasons, including nonspecific infection and replication in normal cells, slow or low viral replication rates, vector clearance and neutralization due to anti-adenoviral immunogenicity, and low oncolytic capacity. These limitations can also lead to inefficient gene transfer or expression when used as delivery vectors.
[0009] These efforts have been aimed at improving replication-competent adenoviruses to address their limitations. These efforts have included modifying components of the adenoviral genome to replicate selectively in tumor cells. Well-characterized modifications include a 24-base pair deletion of the adenoviral E1A gene (delta-24E1A), deletion of the E1B 55K viral gene, and even replacement of viral promoters (such as E1A) with tumor-associated antigen promoters (such as the alpha-fetoprotein promoter or the prostate antigen promoter).
[0010] Despite these examples of selective tumor targeting, the prior art lacks recombinant adenoviral vectors that replicate at significantly increased rates or levels in tumor cells.
[0011] Therefore, there remains a need for oncolytic viral vectors to improve one of their primary mechanisms of action: selectively enhancing viral replication in tumor cells, thereby improving tumor lysis. The present invention addresses this need for oncolytic adenoviral vectors with enhanced viral replication in tumor cells, improved tumor lysis, and improved therapeutic transgene expression.
[0012] All subject matter discussed in the Background is not necessarily prior art, nor should it be assumed to be prior art simply because it is discussed in the Background. Along these lines, any admission that a problem is in the prior art discussed in the Background or a problem related to such subject matter should not be considered prior art unless expressly stated as prior art. Rather, the discussion of any subject matter in the Background should be considered as part of the inventor's solution to a particular problem, which may itself be inventive. Summary of the invention
[0013] The following is a brief summary of the present invention to provide a basic understanding of certain aspects of the present invention. This content is not an exhaustive overview of the present invention. Its purpose is not to identify the key or critical elements of the present invention, or to describe the scope of the present invention. Its only purpose is to present some concepts in a simplified form as a prelude to a more detailed description discussed later.
[0014] We surprisingly found that the insertion of two exogenous promoter / enhancer elements (CMV promoter / enhancer and SV40 early promoter / enhancer) into the adenoviral genome, as well as the previously described modifications of the adenoviral E1A, E1B and E3 gene components, significantly enhanced viral replication in tumor cells and enhanced tumor lysis. We were also surprised to find that this newly described recombinant adenovirus can be used as a vector for delivering one or more therapeutic transgenes, thereby significantly enhancing the expression effect of these transgenes in tumor cells. Although the use of CMV promoter / enhancer or SV40 promoter / enhancer alone has been used to generate recombinant oncolytic adenoviruses, we are not aware of any prior art describing the dual use of promoters in oncolytic viruses, and we are not aware of prior art describing that this dual promoter oncolytic adenovirus that we unexpectedly discovered will result in enhanced tumor-specific viral replication.
[0015] In some embodiments, the present invention relates to oncolytic adenoviruses having viral genome modifications that confer enhanced viral replication.
[0016] In some embodiments, the recombinant oncolytic adenovirus comprises a CMV promoter / enhancer and an SV40 promoter / enhancer inserted into the viral genome.
[0017] In some embodiments, the recombinant oncolytic adenovirus comprises a CMV promoter / enhancer and an SV40 promoter / enhancer inserted into the viral genome, has a partial or complete deletion of the E3 coding region, has an E1A gene comprising a delta-24 deletion, and includes an E1B 55K deletion.
[0018] In a preferred embodiment, the recombinant oncolytic adenovirus comprises a CMV promoter / enhancer inserted into the upstream non-coding region of the adenovirus E1 coding region, comprises an SV40 promoter / enhancer inserted into the adenovirus E3 region, has a partial or complete deletion of the E3 coding region, and has an E1A gene comprising a delta-24 deletion; and includes an E1B 55K deletion.
[0019] Other embodiments of the invention include heterologous nucleic acid sequences encoding one or more therapeutic proteins.
[0020] In some embodiments, the present invention provides an oncolytic adenovirus having enhanced viral replication against tumor cells.
[0021] In a further embodiment, the present invention provides a method for treating a malignancy, preferably cancer, by administering a recombinant oncolytic adenovirus with enhanced replication.
[0022] The details of one or more embodiments are set forth in the following description. Features shown or described in conjunction with one exemplary embodiment may be combined with features of other embodiments. Therefore, any of the various embodiments described herein may be combined to provide further embodiments. If necessary, various aspects of the embodiments may be modified to adopt the concepts of the various patents, applications, and publications identified herein to provide further embodiments. Other features, objects, and advantages will be apparent from the specification, drawings, and claims.
[0023] BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The present invention may be understood by reference to the following description in conjunction with the accompanying drawings, in which:
[0025] Figure 1 Schematic representation of a replication-enhanced oncolytic adenovirus having a CMV promoter / enhancer and an SV40 promoter / enhancer inserted into the adenoviral genome; and a region for inserting heterologous nucleic acid to express one or more therapeutic proteins.
[0026] Figure 2 Schematic representation of a replication-enhanced oncolytic adenovirus having a CMV promoter / enhancer inserted into a noncoding region upstream of the adenoviral E1 coding region, an SV40 promoter / enhancer inserted into the adenoviral E3 region, additional viral genome modifications, and a region for inserting heterologous nucleic acid to express one or more therapeutic proteins.
[0027] Figure 3 Schematic representation of a replication-enhanced oncolytic adenovirus (MEM-288) encoding two transgenes: chimeric CD40 ligand (MEM40) and IFN-beta (IFNβ).
[0028] Figure 4 The dual transgenic expression of different tumor cells after infection with a replication-enhanced oncolytic adenovirus (MEM-288) encoding two transgenes (MEM40 and IFNβ) is shown. After infection with a multiplicity of infection (MOI) = 250 for 2 days, the in vitro expression of MEM40 (flow cytometry) and IFNβ (ELISA) was determined. The IFNβ results also show that the transgenic expression of MEM-288 is under the control of the CMV promoter / enhancer region and lacks a comparison of the SV40 promoter / enhancer compared to MEM-188 carrying only MEM40 or a control oncolytic adenovirus carrying only a GFP reporter transgene (control oAdv).
[0029] Figure 5 Shown is the expression of chimeric CD40 ligand (MEM40) on different tumor cell lines after infection with MEM-188 or MEM-288.
[0030] Figure 6 Shown are the dose- and time-dependent expression of MEM40 on A549 lung tumor cells following infection with MEM-188 or MEM-288.
[0031] Figure 7 Virus titers of A549 cells infected with Ad-GFP (G), MEM-188 (188), and MEM-288 (288) at the indicated multiplicity of infection (MOI) are shown. TM The Adenovirus Titer Immunoassay Kit measures the level of infectious virus released.
[0032] Figure 8 The figure shows the virus titer of A549 cells infected with MEM-188 (188) at an MOI of 10 and the addition of exogenous recombinant IFNβ protein. After freeze-thaw thawing, AD-293 cells were infected with the virus titer using QuickTiter TM The Adenovirus Titer Immunoassay Kit measures the level of infectious virus released.
[0033] Fig. 9 Shown is the enhanced oncolytic activity of MEM-288 containing CMV promoter / enhancer elements and SV40 promoter / enhancer elements against A549 tumor cells as measured by real-time cell analysis (RTCA) compared to a control virus containing CMV promoter / enhancer elements alone.
[0034] Fig.10 Shown is the enhanced oncolytic activity of MEM-288 containing CMV promoter / enhancer elements and SV40 promoter / enhancer elements against H23 tumor cells as measured by real-time cell analysis (RTCA) compared to a control virus containing CMV promoter / enhancer elements alone.
[0035] Fig.11 Shown is the enhanced oncolytic activity of MEM-288 containing CMV promoter / enhancer elements and SV40 promoter / enhancer elements against PC9 tumor cells as measured by real-time cell analysis (RTCA) compared to a control virus containing CMV promoter / enhancer elements alone.
[0036] Fig.12 Shown is the enhanced oncolytic activity of MEM-288 containing CMV promoter / enhancer elements and SV40 promoter / enhancer elements against HCC44 tumor cells as measured by real-time cell analysis (RTCA) compared to a control virus containing CMV promoter / enhancer elements alone.
[0037] Fig.13 Shown are changes after A549 luciferase expressing tumors were implanted into SCID mice and injected intratumorally with Ad-GFP, MEM-188 or MEM-288. Viable tumors were shown at D14 after the first viral injection compared to the baseline before treatment.
[0038] Fig.14 Shown is the ability of Raji human B cell lymphoma cells to survive infection with Ad-GFP, MEM-188 or MEM-288.
[0039] Fig.15 Shown are tumor-specific oncolytic activities of MEM-288, MEM-188, and Ad-GFP oncolytic viruses following infection of A549 tumor cells and cancer-associated fibroblast (CAF) isolates as measured by real-time cell analysis (RTCA).
[0040] Fig.16 Shown is the dose-titrated tumor-specific oncolytic activity of MEM-288 in A549 tumor cells compared to the oncolytic activity of cancer-associated fibroblast (CAF) isolates as determined by real-time cell analysis (RTCA).
[0041] Fig.17 Shown are the percentage of cell survival of untreated (UT) human monocyte-derived dendritic cells infected with Ad-GFP, MEM-188, and MEM-288 at an MOI of 50 for two days.
[0042] Fig.18 Shown is the expression of GFP or chimeric CD40 ligand (MEM40) in the A549 human lung cancer cell line following infection with a replication-enhanced oncolytic adenovirus containing the same E3 adenoviral region deletions found in MEM-288 (E3 6.7k and E3 19k deletions) and also encoding a GFP transgene (GFP; Ad-GFP-2) or MEM-288 oncolytic adenovirus, respectively. For comparison, this Ad-GFP-2 construct was compared with Figure 4 , 7 , 9-17 described in the Ad-GFP control virus construct, which contains an almost complete deletion of the E3 region. Figure (A) shows the expression of GFP in uninfected cells (untreated) or cells infected with Ad-GFP-2 at MOI 10 and 100. Figure (B) shows the expression of MEM40 in uninfected cells (untreated) or cells infected with MEM-288 at MOI 10 and 100. This result shows that at a lower MOI of 10, MEM-288 causes a higher proportion of MEM40 cells than Ad-GFP-2, indicating that MEM-288 may replicate more than Ad-GFP-2.
[0043] Fig.19 The viability of A549 human lung cancer cell line after infection with Ad-GFP-2 or MEM-288 is shown. Ad-GFP-2 and MEM-288 are used to infect cells with the indicated MOI of 1, 10 and 100. After 2 days, the remaining surviving cells are counted and shown as the percentage of untreated cells (UT). This result shows that in all 3 MOIs, MEM-288 has greater oncolytic activity compared with Ad-GFP-2. Therefore, the higher oncolytic activity of MEM-288 is not mainly driven by E3 deletion type, but is unexpectedly highly dependent on the inclusion of SV40 promoter in the E3 region.
[0044] A brief description of the sequence
[0045] SEQ ID NO: 1 shows the nucleotide sequence of the CMV promoter / enhancer inserted between the left inverted terminal repeat (ITR) and the 5' end of the functional E1A region.
[0046] SEQ ID NO: 2 shows the nucleotide sequence of the SV40 early promoter / enhancer inserted between the E3 12.5K and E3 RID-α regions. DETAILED DESCRIPTION
[0047] Various illustrative implementations of the present invention are described below. For the sake of clarity, not all features of an actual implementation are described in this specification. Of course, it should be understood that in the development of any such actual implementation, many implementation-specific decisions must be made to achieve the developer's specific goals, such as complying with system-related and business-related constraints, which will vary from implementation to implementation. In addition, it should be understood that such development work may be complex and time-consuming, but will be a routine task for those of ordinary skill in the art who benefit from the present invention.
[0048] Although the subject matter disclosed herein is susceptible to various modifications and alternative forms, specific embodiments thereof have been shown in the drawings by way of example and are described in detail herein. However, it should be understood that the description of specific embodiments herein is not intended to limit the invention to the specific forms disclosed, but rather, is intended to cover all modifications, equivalents and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
[0049] Adenovirus
[0050] "Adenovirus" (Ad) is a large (about 36 kb) DNA virus that infects humans but also exhibits a broad host range. Physically, an adenovirus is an icosahedral virus containing a double-stranded linear DNA genome. There are approximately 57 serotypes of human adenoviruses, which are classified into six families based on molecular, immunological, and functional criteria. By adulthood, nearly everyone is infected with the more common adenovirus serotypes, with the main effect being cold-like symptoms.
[0051] Adenoviral infection of host cells results in the retention of adenoviral DNA at the body surface, which reduces the potential genotoxicity associated with integrating vectors. In addition, adenoviruses are structurally stable, and no genome rearrangements have been detected after extensive amplification. Adenoviruses can infect most epithelial cells, regardless of the cell cycle stage. So far, adenoviral infection appears to be associated with only mild illnesses such as acute respiratory diseases in humans.
[0052] Oncolytic adenovirus
[0053] There are multiple types of oncolytic viruses under development as anticancer drugs, including adenoviruses (see Russell et al., 2014 Nature Biotechnology and Lawler et al., 2017 JAMA Oncology).
[0054] In selecting or designing a therapeutic oncolytic adenovirus for a desired therapeutic activity, a variety of biological properties can be considered, including: selective targeting of cancer cells for infection, either through natural tropism of cell surface proteins or by engineering the adenovirus to directly target cancer cells; selective replication of cancer cells; attenuation of viral pathogenicity; enhanced lytic activity; modification of the antiviral immune response that can result in rapid clearance of the adenovirus; and modification of systemic antitumor immunity by genetic modification of the adenovirus to incorporate cytokines, immune agonists, or immune checkpoint blockers.
[0055] Replication-competent oncolytic adenoviral vectors have several properties that make them ideal for therapeutic applications, including infectivity of a variety of cell and tumor types, infectivity of non-dividing cells, lack of genomic integration, high titer, ability to carry a transgene, in vitro and in vivo stability, and expression of the transgene. Adenoviral expression vectors include constructs containing adenoviral sequences sufficient to (a) support packaging of the construct and (b) ultimately express a recombinant gene construct that has been cloned therein (if desired).
[0056] Regulation of the biological properties of oncolytic adenoviruses can affect a series of immune interactions that may be beneficial or harmful to cancer treatment. This interaction depends on the specific tumor, the site and extent of the disease, the immunosuppressive tumor microenvironment, the oncolytic virus platform, the dose, time and administration conditions, and the response of individual patients (generally see Aurelian L. "Oncolytic viruses as immunotherapy: progress and remaining challenges", Onco. Targets Ther. 2016, 9: 2627-2637). For example, it has been reported that the presence of adenovirus E3 genes can improve the oncolytic potency of conditionally replicative adenoviruses in vitro and in vivo (see Suzuki K, Alemany R, Yamamoto M and Curiel DT, "The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses", Clin. Cancer Res. November 2002, 8 (11): 3348-59). In particular, the E3-11.6 kDa adenovirus death protein (ADP) is considered to be required for efficient cell death (see Tollefson A, Ryerse J and Scaria A et al., "The E3-11.6-kDa Adenovirus Death Protein (ADP) is Required for Efficient Cell Death: Characterization of Cells Infected with adp Mutants", Virology 1996, 220: 152-162).
[0057] Despite the above advances, the prior art is relatively inadequate with respect to adenoviral vectors that replicate at significantly increased rates or levels in tumor cells to affect one of the primary mechanisms of action of oncolytic adenoviruses: viral replication leading to tumor lysis. Thus, there remains a need for oncolytic viral vectors that improve this primary mechanism of action: selectively enhancing viral replication in tumor cells, thereby improving tumor lysis.
[0058] The present invention provides such an oncolytic adenovirus. We surprisingly found that inserting two exogenous promoter / enhancer elements (CMV promoter / enhancer and SV40 promoter / enhancer) at specific locations in the adenoviral genome, as well as modifications of the previously described adenoviral E1A, E1B and E3 gene components, can significantly enhance viral replication in tumor cells and enhance tumor lysis ( Figure 2 ).
[0059] We were also surprised to find that this newly described recombinant adenovirus can serve as an ideal vector for delivering one or more therapeutic transgenes, thereby enhancing the expression of these transgenes in tumor cells. Members of any of the 57 human adenovirus serotypes (HAdV-1 to 57) may contain heterologous nucleic acids encoding therapeutic proteins. Human Ad5 has been well characterized genetically and biochemically (GenBank M73260; AC 000008). Therefore, in a specific embodiment, the oncolytic adenovirus is a replication-competent Ad5 serotype or a mixed serotype comprising Ad5 components. In some embodiments of the present invention, one or more heterologous sequences may be incorporated into non-essential regions of the adenovirus. In some embodiments of the present invention, one or more heterologous sequences may be integrated downstream of the CMV promoter / enhancer and / or downstream of the SV40 promoter / enhancer. Representative examples of therapeutic proteins encoded by these heterologous genes include cytokines, chemokines, antibodies, and checkpoint inhibitors.
[0060] Promoter / enhancer
[0061] Many promoters work together with heterologous enhancer elements isolated from DNA. Both CMV and SV40 "promoters" described here constitute enhancer and promoter elements. The enhancers in CMV and SV40 "promoters" may be used to increase the expression of adenovirus gene promoters in a typical manner of enhancer action, which may represent a mechanism of increased replication.
[0062] The expression of heterologous nucleic acid may be controlled by a promoter that functions in mammalian cells, preferably human tumor cells. In one embodiment, the promoter-directed expression of heterologous nucleic acid encoding a therapeutic protein is a cytomegalovirus (CMV) promoter / enhancer. In another embodiment, the promoter-directed expression of heterologous nucleic acid encoding a therapeutic protein is a SV40 promoter / enhancer.
[0063] The invention provided herein comprises two promoters / enhancers capable of driving the expression of heterologous nucleic acids encoding proteins. Promoters generally comprise a sequence whose function is to locate the start site of RNA synthesis. The best example is the TATA box, but in some promoters lacking the TATA box, such as the promoter of the mammalian terminal deoxynucleotidyl transferase gene and the promoter of the SV40 early gene (a preferred embodiment of the present invention), discrete elements covering the start site itself help to fix the start position. Additional promoter elements regulate the frequency of transcription initiation. These promoters are generally located in the region 30 to 110 bp upstream of the start site, although it has been shown that promoters also contain functional elements downstream of the start site. In order to place the coding sequence "under the control" of the promoter, it is necessary to position the 5' (5-prime) end of the transcription start site of the transcription reading frame "downstream" (i.e., the 3' (3-prime) end) of the selected promoter. The "upstream" promoter stimulates DNA transcription and promotes the expression of the coding RNA.
[0064] The spacing between promoter elements is often flexible, so that promoter function is retained when elements are inverted or moved relative to each other. In the tk promoter, the spacing between promoter elements can be increased to 50 bp before activity begins to decline. Depending on the promoter, it appears that individual elements can activate transcription synergistically or independently. Promoters may or may not be used in conjunction with an "enhancer," which refers to a cis-acting regulatory sequence that participates in the transcriptional activation of a nucleic acid sequence. In a preferred embodiment of the present invention, a CMV promoter incorporated into a replication-enhanced adenovirus is used together with a CMV enhancer region. In a further preferred embodiment of the present invention, an SV40 promoter incorporated into a replication-enhanced adenovirus is used together with an SV40 enhancer region.
[0065] The promoter may be naturally associated with the nucleic acid sequence and obtained by separating the 5' non-coding sequence located upstream of the coding segment and / or exon. Such a promoter may be referred to as "endogenous". Similarly, an enhancer may be naturally associated with a nucleic acid sequence located downstream or upstream of the sequence. Alternatively, certain advantages may be obtained by positioning the coding nucleic acid fragment under the control of a recombinant or heterologous promoter, which refers to a promoter that is generally not associated with the nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer also refers to an enhancer that is generally not associated with the nucleic acid sequence in its natural environment. Such promoters or enhancers may include promoters or enhancers of other genes, as well as promoters or enhancers isolated from any other adenovirus or prokaryotic or eukaryotic cells, and promoters or enhancers that are not "naturally present", i.e., different elements containing different transcriptional regulatory regions, and / or mutations that change expression.
[0066] In the organelle, cell type, tissue, organ or organism selected for expression, it may be important to use a promoter and / or enhancer that effectively directs the expression of the DNA fragment. Those skilled in the art of molecular biology generally know how to use promoters, enhancers and cell type combinations to express proteins. The promoter used can be constitutive, tissue-specific, inducible and / or used to direct high-level expression of the introduced DNA fragment under appropriate conditions, for example, to facilitate large-scale production of recombinant proteins and / or peptides. The promoter can be heterologous or endogenous. Surprisingly, we found that the SV40 promoter / enhancer containing both the CMV promoter / enhancer upstream of the E1Aδ-24 region and the partially deleted region of the E3 region can significantly increase tumor-specific viral replication and tumor-specific oncolysis by at least 10 to 100 times compared to a control virus lacking the dual promoter feature.
[0067] Adenovirus screening methods for therapeutic applications
[0068] The therapeutic efficacy of the oncolytic adenovirus of the present invention or its variant or derivative can be evaluated by detecting its lytic potential in tumor cells. Tumor cells may include primary tumor cells derived from patient biopsy or surgical resection. Alternatively, tumor cells may include tumor cell lines. The cytolytic activity of the adenovirus of the present invention can be determined by infecting cells with serial dilutions of the adenovirus and determining the cytolytic potency (i.e., IC 50 ) is measured in in vitro tumor cell lines. Specific methods for measuring cytolytic activity may include, but are not limited to, MTS, MTT, and ATP colorimetric assays. Real-time cytotoxicity assays can also be used to determine cytolytic activity.
[0069] The therapeutic index of the oncolytic adenovirus of the invention, i.e., the amount of therapeutic agent that causes a therapeutic effect compared to the amount that causes toxicity, can be calculated by comparing the cytolytic potency of the adenovirus in tumor cell lines with that in matched normal cells.
[0070] The therapeutic utility of the oncolytic adenovirus of the present invention can be further evaluated by evaluating its ability to infect tumor cells and / or normal cells and express functional proteins encoded by the oncolytic adenovirus. An example of the present invention is a replication-enhanced oncolytic virus (MEM-288) encoding a chimeric CD40 ligand (MEM40) under the control of the CMV promoter / enhancer and IFNβ ( Figure 3 ). These proteins can be detected by antibodies that specifically recognize each protein expressed by cells infected with MEM-288. The nucleic acid sequence of the chimeric CD40 ligand (MEM40) is described as ISF35 in U.S. Pat. No. 7,495,090, which is incorporated herein by reference.
[0071] The oncolytic adenoviruses of the invention can be further evaluated for their ability to target tumor cell growth and to reduce tumorigenesis or tumor cell burden in naturally derived or transplanted tumors in syngeneic or xenogeneic tumor models in mice. Tumor burden measured by tumor size, immune protection from tumor rechallenge, and animal survival are all possible measures of therapeutic efficacy and animal tumor models.
[0072] Treatment and administration methods
[0073] In various embodiments of the present invention, a method for treating cancer is also provided, comprising administering an adenovirus as described herein to a subject with cancer. The oncolytic adenovirus of the present invention can be administered by intratumoral injection. However, other delivery routes can also be considered, including intravenous, intraperitoneal, intratracheal, intramuscular, intracranial, endoscopic, intralesional, transdermal, subcutaneous, local or direct injection or infusion.
[0074] In a specific embodiment, a composition as described herein (e.g., a pharmaceutical composition) is used to treat cancer. As described above, the term "cancer" as used herein refers to a large class of diseases characterized by uncontrolled growth of cells in the body. Representative forms of cancer include carcinoma, sarcoma, myeloma, leukemia, lymphoma, and the above-mentioned mixed types. Further examples include, but are not limited to: bile duct cancer, bladder cancer, brain cancer (e.g., glioblastoma), breast cancer, cervical cancer, CNS tumors (e.g., glioblastoma, astrocytoma, medulloblastoma, cranioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, hemangioma, neuroblastoma, and retinoblastoma), colorectal cancer, endometrial cancer, hematopoietic cancer (including leukemia and lymphoma), hepatocellular carcinoma, renal cancer, laryngeal cancer, lung cancer, melanoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, squamous cell carcinoma, and thyroid cancer. The cancer may be diffuse (such as leukemia), include solid tumors (such as sarcomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, and osteosarcoma), or some combination of these tumors (such as metastatic cancer with both solid tumors and disseminated or diffuse cancer cells). For example, any cancer patient who is eligible for autologous or allogeneic stem cell transplantation would be considered a candidate for this therapy.
[0075] In some embodiments, administration can be accomplished by direct administration to a tumor or anterior site of a tumor (eg, following surgical resection or ablative therapy). Administration can be by direct injection or by infusion over a selected period of time.
[0076] Injection directly into a tumor (intratumoral injection) can be accomplished through a thin catheter or cannula.In certain embodiments, the pharmaceutical compositions provided herein can be delivered through a microelectromechanical (MEMS) system under guidance within an MR procedure.
[0077] When administered to a subject, an effective amount of the composition described herein is administered for treatment (e.g., alleviation, reduction, stabilization, prevention of spread, slowing or delaying the progression of cancer or cure). For example, the amount may be sufficient to achieve the effect of reducing or destroying cancer cells or tumor cells, or by inhibiting the growth and / or proliferation of such cells. In order to have clinical efficacy, the composition provided herein can be administered once or multiple times according to a treatment regimen.
[0078] The treatment regimen using the replication-enhanced oncolytic adenovirus of the present invention may include a single administration or multiple administrations. Multiple administrations may be performed according to a periodic schedule and / or in response to one or more indicators of the efficacy of one or more previous administrations, or side effects of one or more previous administrations, as well as other indicators that are obvious to those of ordinary skill in the art who benefit from the present invention.
[0079] The dosage of the pharmaceutical composition used may depend on the particular condition being treated, the severity of the condition, individual patient parameters including age, physical condition, size and weight, duration of treatment, nature of concurrent treatment (if any), the specific route of administration, and other similar factors within the knowledge and expertise of the health care practitioner. In addition, the dosage may depend on the availability of the product.
[0080] Example
[0081] Example 1. Dual promoter replication-enhanced oncolytic adenovirus
[0082] A template replication-enhanced oncolytic adenovirus type 5 ( Figure 1 ): CMV promoter / enhancer represented by SEQ ID NO: 1 and SV40 promoter / enhancer represented by SEQ ID NO: 2. A preferred embodiment of this universal vector construct having the following characteristics is further shown ( Figure 2 ): CMV promoter / enhancer represented by SEQ ID NO: 1 downstream of the left inverted terminal repeat (ITR) and upstream of the functional E1A region; SV40 promoter / enhancer represented by SEQ ID NO: 2 in the E3 region; E1A gene region containing 24 nucleotide deletions; partial or complete deletion of the E3 region; and deletion of the E1b 55k region. This template replication-enhanced oncolytic virus can be further modified, including adding heterologous nucleic acid downstream of the CMV promoter / enhancer or the SV40 promoter / enhancer to express therapeutic proteins.
[0083] Example 2. Construction of a dual-promoter replication-enhanced oncolytic adenovirus encoding two transgenes
[0084] A replication-enhanced oncolytic adenovirus type 5 ( Figure 3): CMV promoter / enhancer represented by SEQ ID NO: 1 downstream of the left inverted terminal repeat (ITR) and upstream of the functional E1A region; SV40 promoter / enhancer represented by SEQ ID NO: 2 in the E3 region; E1A gene region containing 24 nucleotide deletions; partial or complete deletion of the E3 region; and deletion of the E1b 55k region. In addition, heterologous nucleic acids encoding a chimeric CD40 ligand (MEM40) cloned downstream of the CMV promoter / enhancer and IFNβ cloned downstream of the SV40 promoter / enhancer were incorporated. This replication-enhanced oncolytic adenovirus is called MEM-288, which is capable of expressing two proteins that can be easily expressed and detected in tumor cells after infection ( Figure 4 We also directly compared the expression of MEM40 on tumor cells following infection at equivalent infectious titers with MEM-288 or a similar oncolytic adenoviral vector (MEM-188) containing heterologous nucleic acid encoding a chimeric CD40 ligand (MEM40) cloned downstream of the CMV promoter / enhancer but without the SV40 promoter / enhancer and IFNβ transgene insert. MEM-288 expressed higher levels of the MEM40 transgene than MEM-188 in a diverse panel of lung tumor types ( Figure 5 ).
[0085] Example 3. Enhancing viral replication in tumor cells
[0086] A549 tumor cells were infected with increased titers of MEM-288, a replication-enhanced oncolytic adenovirus containing dual CMV and SV40 promoter / enhancer elements ( Figure 6). A direct comparison was made between control viruses (Ad-GFP and MEM-188) with similar feature sets, except that they lacked the SV40 promoter / enhancer elements. MEM-288 resulted in a significant increase in MEM40 expression, which was particularly evident at MOI 10 and MOI 1. At MOI 1, MEM-188 showed no transgene expression, while MEM-288 showed increased expression of MEM40 over time, which was particularly evident on day 6 post infection. These findings suggest that MEM-288 has a greater ability to replicate. To more directly determine whether MEM-288 replicates more efficiently, we performed a standard replication assay based on release of intracellular virus by freeze-thaw lysis. A549 cells were infected with Ad-GFP, MEM-188, and MEM-288 at varying MOIs, and then 293 cells were used to determine intracellular virus levels 2 days later to calculate infectious virus titers using a hexon staining kit from Cell Biolabs, Inc. Ad-GFP infection of A549 produced detectable levels of viral replication starting at an MOI of 10 ( Figure 7 ). The MEM-188 virus produced detectable viral replication starting at an MOI of 1. In contrast, even MOIs of 0.01 and 0.1 for MEM-288 resulted in high levels of viral replication; in addition, infection with MEM-288 at an MOI of 1 or higher resulted in hexon staining signals that were too high to be quantified. These results suggest that MEM-288 may have a 100- to 1000-fold higher replication capacity than other tested viruses lacking the dual promoter / enhancer elements of the present invention.
[0087] MEM-288 differs from MEM-188 in that it has the SV40 promoter / enhancer and the IFNβ transgene. To determine whether the SV40 or IFNβ elements contribute to the higher replication of MEM-288, we added recombinant human IFNβ to MEM-188-infected A549 and then determined viral replication as described above. Importantly, the addition of IFNβ did not increase replication but rather reduced it by approximately 14-fold ( Figure 8 ). This result suggests that the SV40 promoter / enhancer in the E3 region mediates the oncolytic effect and replication enhancement of MEM-288.
[0088] Example 4. Enhanced oncolytic activity
[0089] We infected A549 lung tumor cells with Ad-GFP, MEM-188, or MEM-288 at different multiplicities of infection (MOI) and then determined the number of viable cells. These analyses were further extended to other cell lines and other methods of determining oncolysis, including the use of an impedance-based system (xCELLigence system) that allows for high-precision measurement of cancer cell viability based on adhesion to the plate over time. This real-time cell analysis (RTCA) was performed by plating tumor cell lines at a density of 2500 cells per well and allowing them to attach overnight. Oncolytic viruses were added to the cultures and cancer cell viability measurements were taken every 15 minutes for 120 hours. In four lung cell lines, A549, H23, PC9, and HCC44 (respectively), the viability of the cells was measured every 15 minutes. Figure 9-12 ) we again found that the oncolytic activity of MEM-288 was increased 10- to 100-fold.
[0090] Next, we used SCID mice bearing scA549 tumors expressing firefly luciferase, which allowed quantification of viable tumor cells. After 2 injections of 3 different viruses (10e9 infectious units / injection), MEM-288 significantly reduced tumor growth compared with Ad-GFP and MEM-188 ( Fig.13 ). These results indicate that MEM-288 also has a high oncolytic effect in vivo.
[0091] Example 5. Enhanced oncolytic activity and tumor specificity
[0092] Lymphoid tumor cells resist lysis by oncolytic viruses, including oncolytic adenoviruses. The human B-cell tumor cell line Raji was used to determine the potential effects of MEM-288 on cell viability. Control Ad-GFP and MEM-188 did not show loss of cell viability at MOIs as high as 100 ( Fig.14 In contrast, a clear dose-dependent loss of Raji cell viability was observed following infection with MEM-288 ( Fig.14 ).
[0093] Crucially, this oncolytic effect was specific to tumor cells, as we also found that no significant killing was observed in non-cancer cells such as human lung cancer-associated fibroblasts (CAFs) ( Fig.15 Although MEM-288 had significant oncolytic effects at MOI 1 and MOI 10 using RTCA analysis, two independently derived CAF isolates did not show such significant oncolytic effects ( Fig.15 ).
[0094] Next, we determined the potential fold differences between A549 tumor cells and CAFs using a wide range of MOIs ( Fig.16 ). Comparing the infection dose level that causes 50% cell death (IC50), we found that the IC50 for A549 tumor cells was 0.73, while the IC50 for two independently derived CAF isolates was 45.2 and 122.9, respectively. These results indicate that the ability of MEM-288 to induce cancer cell lysis compared to normal cells is 61.9-fold and 168.3-fold different, respectively ( Fig.16 ).
[0095] We also determined the oncolytic effect of MEM-288 on non-dividing human monocyte-derived dendritic cells (DCs), when CAFs undergo robust growth (i.e., cell division) in vitro. Following infection with MEM-288 or control virus, infection at an MOI of up to 50 typically completely eliminated tumor cells without affecting the viability of DCs ( Fig.17 ). These results indicate that this innovative replication-enhanced oncolytic adenovirus is tumor cell specific.
[0096] Example 6. Enhanced oncolytic activity is not affected by adenovirus E3 regulatory domain
[0097] As mentioned above, the regulation of oncolytic adenovirus biological properties can affect a series of immune interactions that may be beneficial or harmful to cancer treatment. This interaction depends on the specific tumor, the site and extent of the disease, the immunosuppressive tumor microenvironment, the oncolytic virus platform, the dose, time and administration conditions, and the response of individual patients (generally see Aurelian L. "Oncolytic viruses as immunotherapy: progress and remaining challenges", Onco. Targets Ther. 2016, 9: 2627-2637). For example, it has been reported that the presence of the adenovirus E3 gene can improve the oncolytic potency of conditionally replicative adenoviruses in vitro and in vivo (see Suzuki K, Alemany R, Yamamoto M and Curiel DT, "The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses", Clin. Cancer Res. 2002 November, 8(11): 3348-59). In particular, the E3-11.6 kDa adenovirus death protein (ADP) is considered to be required for efficient cell death (see Tollefson A, Ryerse J and Scaria A et al., "The E3-11.6-kDa Adenovirus Death Protein (ADP) is Required for Efficient Cell Death: Characterization of Cells Infected with adp Mutants", Virology 1996, 220: 152-162).
[0098] We examined the potential role of the E3 adenoviral region in our oncolytic adenoviruses by testing two different control GFP-encoding oncolytic adenoviruses, one GFP-encoding Figure 4 , 7 , the almost complete E3 deletion described in 9-17, and another GFP virus (Ad-GFP-2) contains the partial E3 deletion set found in MEM-288 (E3 6.7k and E3 19k deletions).
[0099] Fig.18 The expression of GFP or chimeric CD40 ligand (MEM40) in A549 human lung cancer cell line after infection with Ad-GFP-2 or MEM-288 is shown. Graph (A) shows the expression of GFP in uninfected cells (untreated) or cells infected with Ad-GFP-2 at MOI 10 and 100. Graph (B) shows the expression of MEM40 in uninfected cells (untreated) or cells infected with MEM-288 at MOI 10 and 100. This result shows that at a lower MOI of 10, MEM-288 leads to a higher proportion of MEM40 cells than Ad-GFP-2, indicating that MEM-288 has a greater replication potential than Ad-GFP-2.
[0100] Fig.19 The viability of the A549 human lung cancer cell line after infection with Ad-GFP-2 or MEM-288 is shown. Cells were infected with Ad-GFP-2 and MEM-288 at the indicated MOIs of 1, 10, and 100. After 2 days, the remaining viable cells were counted and shown as a percentage of untreated cells (UT). This result indicates that MEM-288 has greater oncolytic activity than Ad-GFP-2 at all 3 MOIs. In addition, these results reflect the effect of MEM-288 on the oncolytic activity of MEM-288 and MEM-288. Figure 4 , 7 , the results of comparison with the GFP control virus containing an almost complete deletion of the E3 region shown in Figures 9-17.
[0101] Therefore, these results overall indicate that our innovative replication-enhanced adenoviral vectors have greater viral replication and oncolytic activity in most cases, which is independent of any E3 region contribution including partial or complete E3 deletion, which is not obvious to a person skilled in the art based on the prior art described in the above references.
[0102] The particular embodiments disclosed above are illustrative only, as the invention may be modified and practiced in different but equivalent manners which will be apparent to those skilled in the art having the advantage of the teachings herein. For example, the process steps described above may be performed in a different order. Furthermore, the details of construction or design shown herein are not limited except as described in the claims below. It is therefore apparent that the particular embodiments disclosed above may be changed or modified, and all such variations are contemplated within the scope and spirit of the invention. The protection sought herein is therefore as described in the claims below.
Claims
1. An adenovirus vector, in, The adenoviral vector comprises: a. CMV promoter / enhancer inserted into the non-coding region upstream of the adenovirus E1 coding region; b. SV40 promoter / enhancer inserted into the adenovirus E3 region; c. Partial or complete deletion of the E3 coding region; d. E1A gene containing the delta-24 deletion; e.E1B 55K deletion; f. wherein the CMV promoter / enhancer is operably linked to a heterologous nucleic acid sequence encoding MEM40; and g. wherein the SV40 promoter / enhancer is operably linked to a heterologous nucleic acid sequence encoding IFNβ, The CMV promoter / enhancer is located between the left inverted terminal repeat sequence (ITR) and the 5' end of the functional E1A region, and the SV40 promoter / enhancer is located between the E3 12.5K and E3 RID-α regions.
2. The adenoviral vector according to claim 1, in, The adenovirus is serotype 5.
3. The adenoviral vector according to claim 1, in, a. the CMV promoter / enhancer comprises the nucleotide sequence of SEQ ID NO: 1; and b. The SV40 promoter / enhancer comprises the nucleotide sequence of SEQ ID NO:
2.
4. The adenoviral vector according to claim 1, in, The virus has enhanced replication specific to certain cell types.
5. The adenoviral vector according to claim 4, in, The cell type is a tumor cell.
6. The replication-enhanced adenoviral vector according to claim 1, in, The CMV promoter / enhancer comprises the nucleotide sequence of SEQ ID NO:
1.
7. The adenoviral vector according to claim 1, in, The SV40 promoter / enhancer comprises the nucleotide sequence of SEQ ID NO:
2.
8. Use of an effective amount of the adenoviral vector according to any one of claims 1 to 7 in the preparation of a medicament for treating a malignant tumor in a subject.
9. The use according to claim 8, in, The malignancy is cancer.
10. The use according to claim 9, in, The subject is a human.
Citation Information
Patent Citations
Nucleic acids encoding chimeric CD154 polypeptides
US7495090B2
Conditionally replicative adenovirus to target the Rb and Rb-related pathways
US20030138405A1
Armed replication-competent oncolytic adenoviruses
US20180169271A1
